Research graph
References from Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease. Local targets link to admitted publications; unresolved targets remain external evidence.
The neuropathological diagnosis of Alzheimer’s disease.
10.1186/s13024-019-0333-5 · 2019 · External reference
The role of amyloid PET in imaging neurodegenerative disorders: a review.
10.2967/jnumed.121.263195 · 2022 · External reference
Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup.
10.1002/alz.13859 · 2024 · External reference
A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research.
10.1016/j.nicl.2025.103765 · 2025 · External reference
The role of amyloid-ß and tau PET in the new era of Alzheimer disease therapies.
10.2967/jnumed.124.268339 · 2025 · External reference
Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.
10.1002/alz.14338 · 2025 · External reference
Donanemab in early symptomatic Alzheimer Disease: the TRAILBLAZER-ALZ 2 randomized clinical trial.
10.1001/jama.2023.13239 · 2023 · External reference
Lecanemab in early Alzheimer’s disease.
10.1056/nejmoa2212948 · 2023 · External reference
TRAILBLAZER-ALZ 4: a phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer’s disease.
10.1002/alz.70293 · 2025 · External reference
Lecanemab: appropriate use recommendations.
10.14283/jpad.2023.30 · 2023 · External reference
Donanemab: appropriate use recommendations.
10.1016/j.tjpad.2025.100150 · 2025 · External reference
Treatment-related amyloid clearance (TRAC): a framework to characterize patients in the era of anti-amyloid therapies.
10.1002/alz.70997 · 2025 · External reference
The AHEAD 3-45 Study: design of a prevention trial for Alzheimer’s disease.
10.1002/alz.12748 · 2023 · External reference
Donanemab in preclinical Alzheimer’s disease: screening and baseline data from TRAILBLAZER-ALZ 3.
10.1002/alz.70662 · 2025 · External reference
Quantification supports amyloid PET visual assessment of challenging cases: results from the AMYPAD Diagnostic and Patient Management Study.
10.2967/jnumed.124.268119 · 2025 · External reference
The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.
10.1016/j.jalz.2014.07.003 · 2015 · External reference
Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer’s disease neuropathology.
10.1016/j.jalz.2018.09.001 · 2019 · External reference
Centiloid recommendations for clinical context-of-use from the AMYPAD consortium.
10.1002/alz.14336 · 2024 · External reference
Statistical evaluation of a biomarker.
10.1097/aln.0b013e3181d47604 · 2010 · External reference
2. Diagnosis and classification of diabetes: standards of care in diabetes-2025.
10.2337/dc25-s002 · 2025 · External reference
Patients with “gray zone” PSA levels: application of prostate MRI and MRS in the diagnosis of prostate cancer.
10.1002/jmri.28505 · 2023 · External reference
2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
10.1161/cir.0000000000000678 · External reference
Acceptable performance of blood biomarker tests of amyloid—recommendations from the Global CEO Initiative on Alzheimer’s Disease.
10.1038/s41582-024-00977-5 · 2024 · External reference
Genetics of Alzheimer disease.
10.1177/0891988710383571 · 2010 · External reference
Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer’s disease from late-onset amyloid deposition.
10.1016/j.jalz.2018.01.002 · 2018 · External reference
Variant-dependent heterogeneity in amyloid ß burden in autosomal dominant Alzheimer’s disease: cross-sectional and longitudinal analyses of an observational study.
10.1016/s1474-4422(21)00375-6 · 2022 · External reference
Molecular neuroimaging in dominantly inherited versus sporadic early-onset Alzheimer’s disease.
10.1093/braincomms/fcae159 · 2024 · External reference
Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type.
10.1017/s1041610297004870 · 1997 · External reference
“Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician.
10.1016/0022-3956(75)90026-6 · 1975 · External reference
Categorisation and minoritisation.
10.1136/bmjgh-2020-004508 · 2020 · External reference
Updated guidance on the reporting of race and ethnicity in medical and science journals.
10.1001/jama.2021.13304 · 2021 · External reference
Amyloid and APOE e4 interact to influence short-term decline in preclinical Alzheimer disease.
10.1212/wnl.0000000000000431 · 2014 · External reference
Defining the lowest threshold for amyloid-PET to predict future cognitive decline and amyloid accumulation.
10.1212/wnl.0000000000011214 · 2021 · External reference
Validation of amyloid PET positivity thresholds in Centiloid: a multisite PET study approach.
10.1186/s13195-021-00836-1 · 2021 · External reference
Concordance between amyloid-PET quantification and real-world visual reads.
10.1001/jamaneurol.2025.2218 · 2025 · External reference
Assessing a mixture model for clustering with the integrated completed likelihood.
10.1109/34.865189 · 2000 · External reference
Index for rating diagnostic tests.
10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3 · 1950 · External reference
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.
10.1001/jama.2015.4668 · 2015 · External reference
Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers.
10.1186/s13195-019-0478-z · 2019 · External reference
Characterizing amyloid-positive individuals with normal tau PET levels after 5 years: an ADNI study.
10.1212/wnl.0000000000200287 · 2022 · External reference
Quantification of baseline amyloid PET in individuals with subjective cognitive decline can identify risk of amyloid accumulation and cognitive worsening: the FACEHBI study.
10.1007/s00259-025-07270-7 · 2025 · External reference
Calibration of multisite raters for prospective visual reads of amyloid PET scans.
10.1002/alz.70732 · 2025 · External reference
Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease.
10.1186/s13195-020-00587-5 · 2020 · External reference
National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease.
10.1016/j.jalz.2011.10.007 · 2012 · External reference
10.4135/9781446221570
10.4135/9781446221570 · 2010 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
